US 12,390,469 B2
SHP2 inhibitor monotherapy and uses thereof
Farbod Shojaei, San Diego, CA (US); Jill M. Ricono, Encinitas, CA (US); Robert Goodenow, San Clemente, CA (US); and Mireille Gillings, San Diego, CA (US)
Assigned to HUYABIO International, LLC, San Diego, CA (US)
Filed by HUYABIO International, LLC, San Diego, CA (US)
Filed on May 4, 2022, as Appl. No. 17/736,908.
Claims priority of provisional application 63/320,991, filed on Mar. 17, 2022.
Claims priority of provisional application 63/184,710, filed on May 5, 2021.
Prior Publication US 2022/0370458 A1, Nov. 24, 2022
Int. Cl. A61K 31/519 (2006.01); A61K 31/506 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/506 (2013.01); A61P 35/00 (2018.01)] 26 Claims
 
1. A method of treating cancer in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of a compound having the structure of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof:

OG Complex Work Unit Chemistry
wherein said cancer is non-small cell lung cancer, esophageal cancer, stomach cancer, or brain tumor; and wherein said patient has failed at least one anti-cancer agent therapy, wherein said anti-cancer agent is an EGFR TK inhibitor.